Age-dependent bone mineral density responses to gender-affirming hormone therapy in transgender individuals: a one-year prospective study.

ABSTRACT:

Purpose

Evidence on the skeletal effects of gender-affirming hormone therapy (GAHT) in transgender individuals remains limited, especially across age groups. Individuals assigned male at birth (AMAB) often show reduced bone mineral density (BMD) even before GAHT, whereas findings in those assigned female at birth (AFAB) are more variable. Given the key role of adolescence and early adulthood in peak bone mass, timely skeletal assessment is essential. This study compared BMD before and after one year (1-y) of GAHT to age-matched cisgender controls.

Methods

Prospective observational study involving 269 adults (162 transgender and 107 cisgender controls) conducted at the University Hospital of Padua (January 2020-November 2024). Dual-energy X-ray absorptiometry (DXA) was perfor

SUBMITTER: Ceolin C 

PROVIDER: S-EPMC12640344 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature